{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:50Z","timestamp":1793779250587,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.diabet.2022.101325","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:33:41Z","timestamp":1643736821000},"page":"101325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andre J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2022.101325_bib0001","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2022.101325_bib0002","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2022.101325_bib0003","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2022.101325_bib0004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diabet.2019.04.001","article-title":"Assessment of the benefit-risk balance of SGLT2 inhibitors: commentary on a new \u2018French paradox\u2019","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2022.101325_bib0005","first-page":"1","article-title":"Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","author":"See","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.diabet.2022.101325_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.diabres.2018.06.008","article-title":"Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"143","author":"Scheen","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2022.101325_bib0007","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabet.2022.101325_bib0008","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2022.101325_bib0009","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2022.101325_bib0010","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2022.101325_bib0011","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejvs.2021.09.031","article-title":"Initiation of SGLT2 Inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis","volume":"62","author":"Rodionov","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.diabet.2022.101325_bib0012","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1038\/s41598-021-86516-4","article-title":"Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2022.101325_bib0013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2022.101325_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.deman.2022.100054","article-title":"Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies","author":"Scheen","year":"2022","journal-title":"Diabetes Epidemiol Management"},{"key":"10.1016\/j.diabet.2022.101325_bib0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","article-title":"The safety of gliptins: updated data in 2018","volume":"17","author":"Scheen","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabet.2022.101325_bib0016","article-title":"Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: a meta-analysis","author":"Du","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabet.2022.101325_bib0017","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2022.101325_bib0018","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabres.2017.03.009","article-title":"Cardiovascular outcome studies with incretin-based therapies: comparison between DPP-4 inhibitors and GLP-1 receptor agonists","volume":"127","author":"Scheen","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2022.101325_bib0019","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","article-title":"Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden","volume":"7","author":"Svanstrom","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2022.101325_bib0020","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2022.101325_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107803","article-title":"Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: a network meta-analysis","volume":"35","author":"Qiu","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2022.101325_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial","volume":"12","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.diabet.2022.101325_bib0023","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2022.101325_bib0024","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor","volume":"179","author":"Helmstadter","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabet.2022.101325_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like peptide-1 receptor action in the vasculature","volume":"111","author":"Almutairi","year":"2019","journal-title":"Peptides"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363622000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363622000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:58:35Z","timestamp":1761130715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363622000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1262363622000088"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2022.101325","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2022.101325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101325"}}